Draft legislation has emerged that ostensibly would boost rapid innovation to combat the coronavirus. Bottom line: The bill is a mixed bag with a lot of questions… The Facilitating Innovation to Fight Coronavirus Act appears to be an attempt to bring any and all viable medical inventions to bear, as quickly as possible, in our fight to defeat COVID-19, which is absolutely to be commended. Despite attempts to mitigate the harm that outright eminent domain on patent rights (vigorously advocated by some) would certainly cause, the legislation needs more work.
Recent Posts
- Other Barks & Bites for Friday, July 26: New Group Registration for Frequently Updated News Websites, Trade Secret Claims Against TikTok Survive Dismissal, and USPTO’s Estoppel Provisions in IPR Proceedings Upheld
- Call Off Chicken Little: The Sky is Not Falling for Skinny Labeling After GSK v. Teva
- CAFC Committee Recommends Another Year of Sanctions Against Newman
- Massie Tells House IP Subcommittee Witnesses He’s ‘Appalled’ By Proposals to Rein in ITC’s Patent Powers
- CAFC Invalidates Remaining Claim on Data Transmission Patent, Remands Substitute Claims for Collateral Estoppel Determination